FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 17:39:49 03/06/2024 BST | ||
| 5.33 EUR | -15.66% |
|
| 1 month | +58.00% | ||
| 3 months | +189.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 5.33 | -15.66% |
| 31/05/24 | 6.32 | -9.84% |
| 30/05/24 | 7.01 | +0.86% |
| 29/05/24 | 6.95 | +1.46% |
| 28/05/24 | 6.85 | +19.34% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 05:39 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD5K2L |
| ISIN | DE000SD5K2L6 |
| Date issued | 21/04/2021 |
| Strike | 65.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.73 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.05 € |
| Spread % | 0.93% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
